RDD Pharma is a privately held specialty pharma company focused on fast-track development and commercialization of innovative therapeutics for anorectal diseases and lower-gastrointestinal tract disorders. The company has clinical and pre-clinical stage products, which serve significant unmet needs. RDD-0315 for fecal incontinence, an indication for which there is no approved Rx product, has completed a Phase 2a study in Europe. The European Medicines Agency has granted RDD-0315 Orphan Drug status in spinal cord injury patients. An IND was filed in the US on May 30, 2018. RDD is also initiating a study for RDD-1609 for the treatment of pruritus ani.
Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.
Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.
Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).
Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.